Company profile

Journey Medical Corp

NASDAQ:DERMBiotechnology: Pharmaceutical Preparations

Drug pipeline (4)

AssetStageRevenueTrialsStatus
CROTAMITONapproved0
GLYCOPYRRONIUM TOSYLATEapproved0
Minocycline Hydrochlorideapproved0
SULCONAZOLE NITRATEapproved0

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (10)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT05452785phase1completed2022-05-072022-05-25Journey Medical CorporationA Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects
NCT02016885phase2completed2013-11-012014-09-01Journey Medical CorporationA Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
NCT05296629phase3completed2022-03-142023-06-30Journey Medical CorporationA Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
NCT03880266phase2completed2019-02-222019-05-24Journey Medical CorporationA Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
NCT05343455phase3completed2022-03-292023-06-30Journey Medical CorporationA Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

FDA applications (9)

ApplicationTypeApplicantProducts
NDA 006927NDAJOURNEY MEDICAL CORP
NDA 009112NDAJOURNEY MEDICAL CORP
NDA 018737NDAJOURNEY MEDICAL CORP
NDA 018738NDAJOURNEY MEDICAL CORP
NDA 201922NDAJOURNEY MEDICAL CORP